October 3rd 2022
This week's edition of the Mainstream Patient features stories about recommended acne solutions from dermatologists, Latinx-owned beauty brands, the latest skin care trend of "skin energy," and more.
September 15th 2022
Burst CME: Improving Outcomes for Your Patient with Vitiligo
View More
Burst CME: Improving Outcomes for Your Patient with Vitiligo
View More
Individualizing Treatment in Moderate-to-Severe Atopic Dermatitis through Improved Clinician-Patient Communication
View More
Clinical ConsultationsTM: Focusing on Fabry Disease in Females: Individualizing Diagnostic and Counseling Plans to Improve Long-Term Outcomes
View More
Individualizing Treatment in Moderate-to-Severe Atopic Dermatitis through Improved Clinician-Patient Communication
View More
22nd Annual International Congress on the Future of Breast Cancer® East
View More
22nd Annual International Congress on the Future of Breast Cancer® East
View More
4th Annual International Congress on the Future of Women’s Health™
07/22/2023
View More
22nd Annual International Congress on the Future of Breast Cancer® West
View More
22nd Annual International Congress on the Future of Breast Cancer® West
View More
An Animated View of Alopecia Areata to Advance Our Approaches to Patient Management
View More
An Animated View of Alopecia Areata to Advance Our Approaches to Patient Management
View More
6th Annual Advanced Practice Collaborative
09/08/2023-09/09/2023
View More
Advances in™ Hidradenitis Suppurativa (HS): Optimizing the Management Approach with Available and Emerging Treatments
View More
Advances in™ Hidradenitis Suppurativa (HS): Optimizing the Management Approach with Available and Emerging Treatments
View More
Medical Crossfire®: Diagnostic and Clinical Considerations in Cutaneous T-Cell Lymphoma for the Dermatologist and the Collaborative Cancer Team
View More
Medical Crossfire®: Diagnostic and Clinical Considerations in Cutaneous T-Cell Lymphoma for the Dermatologist and the Collaborative Cancer Team
View More
Medical Crossfire®: Diagnostic and Clinical Considerations in Cutaneous T-Cell Lymphoma for the Dermatologist and the Collaborative Cancer Team
View More
7th Annual New York Cardio-Endo-Renal Collaborative (NY CERC)
10/21/2023
View More
7th Annual New York Cardio-Endo-Renal Collaborative (NY CERC)
10/21/2023
View More
Best Practice in the Multidisciplinary Care of the Patient with HS
View More
Addressing Challenges in the Management of HS in Special Populations
View More
Best Practice in the Multidisciplinary Care of the Patient with HS
View More
Addressing Challenges in the Management of HS in Special Populations
View More
Clinical Conversations With the Cancer Care Team: Discussing the Impact of Social Inequities on Treatment Outcomes in Triple-Negative Breast Cancer
View More
Clinical Conversations With the Cancer Care Team: Discussing the Impact of Social Inequities on Treatment Outcomes in Triple-Negative Breast Cancer
View More
Patient, Provider, and Caregiver Connection™: Incorporating the Patient Journey into HS Diagnosis and Management Practices
View More
Patient, Provider, and Caregiver Connection™: Incorporating the Patient Journey into HS Diagnosis and Management Practices
View More
Patient, Provider, and Caregiver Connection™: Incorporating the Patient Journey into HS Diagnosis and Management Practices
View More
Patient, Provider, and Caregiver Connection™: Incorporating the Patient Journey into HS Diagnosis and Management Practices
View More
Melanoma risk significant among pregnant women
January 21st 2016Study finds women diagnosed with malignant melanoma during their pregnancy or within one year of giving birth were more than five times more likely to die than women who weren't pregnant. Routine skin examinations may need to be included as part of postpartum appointments.
Estrogen replacement therapy benefits variety of skin concerns
September 1st 2012Eight years after the Women's Health Initiative (WHI) linked estrogen supplementation to breast cancer and heart disease, the impact of estrogen withdrawal is obvious in a less-than-obvious location; hormone-deficient vulvar disease is becoming more common, according to F. William Danby, M.D.
Bioidentical hormone replacement therapy in dermatology draws mixed reviews
August 1st 2012The use of bioidentical hormone replacement therapy (BHRT) in dermatology is preferable to using synthetic hormones because potential overdose is less hazardous, and bioidentical hormones are not known to be carcinogenic, says Julie T. Hunter, M.D., founder and director of Wholistic Dermatology in Beverly Hills, Calif.
Polycystic ovary syndrome treatment requires holistic approach
August 1st 2012For young women with polycystic ovary syndrome (PCOS), dermatologists must diagnose the underlying hormonal issues to best treat the related skin symptoms, explains Helen M. Torok, M.D., medical director, Trillium Creek Dermatology & Surgery, Medina, Ohio.
Vulvar disease, related disorders needn't intimidate dermatologists
September 1st 2011Although treating patients with vulvar disorders can be challenging, confidence and compassion go a long way toward helping these patients. Sometimes, dermatologists allow themselves to be intimidated by the idea that vulvar and mucosal problems differ vastly from the usual issues they treat.
Azathioprine side effects may be misunderstood, overstated
June 1st 2011Although azathioprine requires caution and ongoing patient monitoring, some say their side effects are less severe than many patients - and some dermatologists - think. Even some medically oriented dermatologists express the concern that "these pills will wreck your liver," which overstates the actual clinical risk, says Neil Shear, M.D.
Continuing medical education changes include physician self-evaluation
April 1st 2011Physicians immersed in the world of continuing medical education (CME) say big changes are happening. And doctors of all specialties, including dermatology, will be affected by the emerging CME focus: individual outcomes improvement.
Malignant transformation of nevi unlikely in pregnant patients
November 1st 2010Melanocytic nevi always have the potential to change in size, shape and color regardless of when they first appear in the skin, or the age of the patient. A recent study shows that though some nevi demonstrate dynamic change throughout a pregnancy, there does not appear to be an increased risk of malignant transformation of these nevi, nor is there an association between changing nevi and melanoma.
New assay helps physicians distinquish dermatoses unique to pregnancy
August 1st 2010For many pregnant women, their bellies aren't the only things popping out during their nine months of gestation. Skin eruptions can plague expectant women any time during pregnancy. While some dermatoses can be simply uncomfortable, others can pose a risk to the unborn fetus.
Nonablative fractional photothermolysis improves postpartum striae rubra
May 1st 2010Postpartum striae rubra is common, and in Asian skin, these lesions can progress to become hyperpigmented striae distensae. Results from a consecutive case series show the utility of nonablative fractional photothermolysis for treating this problem.
Acne treatment in women requires detailed history, systematic approach
February 3rd 2010Strategies for treating adult female acne include taking detailed patient histories, checking for endocrine abnormalities when indicated and, in many cases, prescribing oral contraceptives also approved for acne, according to an expert.
Confusion on scar diagnosis; deciphering three ICD-9 codes
December 1st 2006Q A patient had a biopsy and the pathology report showed the lesion to be a basal cell carcinoma. We schedule the patient back for an excision. We sent the excision tissue out again. The final pathology came back showing no residual cancer cells; only scar tissue.
IL-1a, Propionibacterium acnes and retinoids comprise key players
November 1st 2006Retinoids affect the inflammatory pathways of acne lesion development indirectly via their ability to normalize hyperkeratinization. However, they also exert direct immunomodulatory effects by competing with transcription factors like AP-1.